Goldman Recaps Halozyme (HALO) Feasibility Study Annoucement, Remains Sidelined

October 16, 2023 9:55 AM EDT Send to a Friend
Goldman Sachs analyst Corinne Jenkins reiterated a Neutral rating and $44.00 price target on Halozyme Therapeutics (NASDAQ: HALO)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login